Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Sustained-release pramipexole in the treatment of Parkinson’s disease

https://doi.org/10.14412/2074-2711-2012-373

Full Text:

Abstract

Dopamine (DA) receptor agonists ensure stimulation of DA receptors in the brain, by compensating for dopaminergic deficiency in Parkinson’s disease (PD). Since 1996, pramipexole has been used to treat early and extensive PD stages; its clinical efficacy has been proven in many double-blind randomized placebo-controlled and open-labeled trials. Since 2009 the European countries and the USA has used extendedrelease pramipexole (ERP) that is given once daily. Its benefits are stabilized plasma drug concentrations, 24-hour action, which provides continuous dopaminergic stimulation ofpostsynaptic receptors for the prevention and therapy of already existing motor fluctuations and drug-induced dyskinesias. Once-daily dosing of ERP increases the adherence of a patient with PD to regular treatment. Two (extended- and immediate-release) formulations of pramipexole differ only in the release rate for the active ingredient from the contents of a tablet. Both formulations contain the same active ingredient, have the similar profile of interacting with DA receptors, and show pharmacotherapeutic efficacy.

About the Author

Natalia Vladimirovna Fedorova

Department of Neurology, Russian Medical Academy of Postgraduate Education; Center for Extrapyramidal Diseases, Moscow


References

1. <div><p>Нодель М.Р., Артемьев Д.В., Яхно Н.Н. Эффективность дофаминового агониста мирапекса при болезни Паркинсона. Нев-рол журн 1999;6(4):45-9.</p><p>Федорова Н.В., Смоленцева И.Г., Левин О.С. Применение агонистов дофаминовых рецепторов при болезни Паркинсо на. РМЖ 2000;8(15-16):643-7.</p><p>Moller C., Oertel W.H. Pramipexole in the treatment of Parkinson’s disease: new developments. Exp Rev Neurother 2005;5(5):581-6.</p><p>Рarkinson Study Group. A randomized controlled trial comparing Pramipexole with Levodopa in early Parkinson’s disease: design and methods of the CALM-PD study. J Clin Neuropharmakol 2000;23(1):34-44.</p><p>Navan P., Findley L.J., Pearce R.G. et al. A randomly assigned double-blind cross-over study examining the relative antiparkinsonian tremor effects of pramipexole and pergolide. Eur J Neurol 2005;12(1):1-8.</p><p>Barone P., Poewe W., Albrecht S. et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomized, double-blind, placebo-controlled trail. Lancet Neurol 2010;9:573-80.</p><p>Oertel W.H., Hoglinger G.U., Caraceni T. et al. Depression in Parkinson’s disease Adv Neurol 2001;86:373-83.</p><p>Drevets W.C. Functional neuroimaging studies of depression: the anatomy of melancholia. Ann Rev Med 1998;49:341-61.</p><p>Grosset K.A., Bone I., Grosset D.G. Suboptimal medication adherence in Parkinson’s disease. Mov Dis 2005;20:1502-7.</p><p>Grosset D., Antonini A., Caneci M. et al. Adherence to antiparkinson medication in a multicenter European study. Mov Dis 2009;24:826-32.</p><p>Claudrine M., Chwieduk, Monique P. Curran. Pramipexole extended-release in Parkinson’s disease. CNS Drugs 2010;24(4):327-36.</p><p>Poewe W.H., Barone P., Hauser R.A. et al. Pramipexole extended-release is effective in early Parkinson’s disease. Mov Dis 2009;24(Suppl. 1):273.</p><p>Salin L., Hauser R., Koester J. Doubleblind evaluation of maintenance of efficacy of pramipexole extended-release in early Parkinson’s disease. Proceedings of the 61st Annual Meeting of the American Academy of Neurology. USA, 2009. Abs. P06.150. Neurology 72:11.</p><p>Hauser R., Salin L., Koester J. Double-blind evolution of pramipexole extended-release (ER) in early Parkinson’s disease. Neurology 2009;72(Suppl. 3)11:A412-3.</p><p>Schapira A.H., Barone P., Hauser R.A. et al. Efficacy and safety of pramipexole extended-release for advanced Parkinson's disease. Mov Dis 2009;24(Suppl. 1):277-8.</p><p>Rascol O., Barone P., Debieuvre C. et al. Easy switching from immediate- to extended-release pramipexole in early Parkinson's disease the same daily dosage. Mov Dis 2009;24 (Suppl. 1):362.</p><p>Rascol O., Barone P., Debiuvre D. et al. Overnight switching from immediate- to extended-release (ER) in early Parkinson’s disease. Neurology 2009;72(11):А320.</p><p>Mizuno Y., Yamamoto M., Kuno S. et al. Efficacy of pramipexole extended release (ER) and switching from immediate release (IR) ER in Japanese advanced Parkinsons disease (PD) patients. Proceedings of the 18 th WFN World Congress on Parkinson’s Disease and Related Disordes. Miami Beach. USA, 2009. Poster 2.192.</p></div><br />


For citation:


Fedorova N.V. Sustained-release pramipexole in the treatment of Parkinson’s disease. Neurology, Neuropsychiatry, Psychosomatics. 2012;4(1):112-116. (In Russ.) https://doi.org/10.14412/2074-2711-2012-373

Views: 436


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)